The competition between Sarepta , Pfizer and Solid Biosciences to market a therapy for the genetic genetic disorder Duchenne muscular dystrophy ( DMD ) has intensified after safety problems emerged from Solid ’s clinical tests . Shares in Sarepta , which has already launched a treatment called Exondys 51 for certain genetic variations , rose 15 % after the problems emerged following an early stage study on Pfizer ’s product . Shares of Pfizer were marginally up in midday trading, while Sarepta shares were up 15% and Solid Biosciences was up about 10%. Sarepta , meanwhile , had reported promising results from its own study into the disorder , which affected one male in 3,500 - 5,000 . Pfizer said no more patients would be trialled until it had won regulatory approval .
The competition between Sarepta , Pfizer and Solid Biosciences to market a therapy for the genetic genetic disorder Duchenne muscular dystrophy ( DMD ) has intensified after safety problems emerged from Solid ’s clinical tests . Shares in Sarepta , which has already launched a treatment called Exondys 51 for certain genetic variations , rose 15 % after the problems emerged following an early stage study on Pfizer ’s product . Sarepta , meanwhile , had reported promising results from its own study into the disorder , which affected one male in 3,500 - 5,000 . Pfizer said no more patients would be trialled until it had won regulatory approval .